These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of an intervention on the prescription of aliskiren after new evidence on safety reported. Rosich Martí I; Allepuz A; Rodriguez Palomar G; Ortin Font F; Soler Cera M Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):91-96. PubMed ID: 27859873 [TBL] [Abstract][Full Text] [Related]
4. Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study. Mahmoudpour SH; Asselbergs FW; Souverein PC; de Boer A; Maitland-van der Zee AH Br J Clin Pharmacol; 2018 Oct; 84(10):2365-2372. PubMed ID: 29943849 [TBL] [Abstract][Full Text] [Related]
5. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN. Mayyas F; Bataineh W; Jarab A Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537 [TBL] [Abstract][Full Text] [Related]
6. Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study. Farcas A; Leucuta D; Bucsa C; Mogosan C; Dumitrascu D Int J Clin Pharm; 2016 Dec; 38(6):1390-1397. PubMed ID: 27677980 [TBL] [Abstract][Full Text] [Related]
7. Discontinuation of angiotensin-converting enzyme inhibitors: a cohort study. Wong MC; Lau RK; Jiang JY; Griffiths SM J Clin Pharm Ther; 2012 Jun; 37(3):335-41. PubMed ID: 22023456 [TBL] [Abstract][Full Text] [Related]
8. Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Gregg LP; Richardson PA; Herrera MA; Akeroyd JM; Jafry SA; Gobbel GT; Wydermyer S; Arney J; Hung A; Matheny ME; Virani SS; Navaneethan SD Am J Nephrol; 2023; 54(3-4):126-135. PubMed ID: 37231800 [TBL] [Abstract][Full Text] [Related]
9. [Assessment of the utilization of angiotensin receptor blockers in hypertension]. Peña Cabia S; Ricote Lobera I; Santos Mena B; Hidalgo Correas FJ; Climent Florez B; García Díaz B Farm Hosp; 2013; 37(5):394-8. PubMed ID: 24128102 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors Following Contemporary Treatments in Patients with Acute Myocardial Infarction: Results from the Korean Working Group in Myocardial Infarction (KorMI) Registry. Song PS; Seol SH; Seo GW; Kim DK; Kim KH; Yang JH; Hahn JY; Gwon HC; Ahn Y; Jeong MH; Song YB; Kim DI; Am J Cardiovasc Drugs; 2015 Dec; 15(6):439-49. PubMed ID: 26153396 [TBL] [Abstract][Full Text] [Related]
11. Dual renin-angiotensin-aldosterone blockade: Implementation of published research and Dear Doctor letters in ambulatory care: A retrospective observational study using prescription data. Angelow A; Ploner T; Grimmsmann T; Walker J; Chenot JF Pharmacoepidemiol Drug Saf; 2020 May; 29(5):530-537. PubMed ID: 32162407 [TBL] [Abstract][Full Text] [Related]
12. More on the "Triple Whammy": antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury - a case/non-case study in the French pharmacovigilance database. Fournier JP; Sommet A; Durrieu G; Poutrain JC; Lapeyre-Mestre M; Montastruc JL; Ren Fail; 2014 Aug; 36(7):1166-8. PubMed ID: 24826803 [TBL] [Abstract][Full Text] [Related]
13. Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. Mahmoudpour SH; Baranova EV; Souverein PC; Asselbergs FW; de Boer A; Maitland-van der Zee AH; Br J Clin Pharmacol; 2016 Dec; 82(6):1647-1659. PubMed ID: 27524468 [TBL] [Abstract][Full Text] [Related]
14. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. Mansfield KE; Nitsch D; Smeeth L; Bhaskaran K; Tomlinson LA BMJ Open; 2016 Dec; 6(12):e012690. PubMed ID: 28003286 [TBL] [Abstract][Full Text] [Related]
15. Prescription in patients with chronic heart failure and multimorbidity attended in primary care. Frigola-Capell E; Verdú-Rotellar JM; Comin-Colet J; Davins-Miralles J; Hermosilla E; Wensing M; Suñol R Qual Prim Care; 2013; 21(4):211-9. PubMed ID: 24041138 [TBL] [Abstract][Full Text] [Related]
16. Treatment with Optimal Dose Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Has a Positive Effect on Long-Term Survival in Older Individuals (Aged >70 Years) and Octogenarians with Systolic Heart Failure. Sargento L; Simões AV; Longo S; Lousada N; Dos Reis RP Drugs Aging; 2016 Sep; 33(9):675-83. PubMed ID: 27568454 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Pucci M; Sarween N; Knox E; Lipkin G; Martin U Expert Rev Clin Pharmacol; 2015 Mar; 8(2):221-31. PubMed ID: 25612630 [TBL] [Abstract][Full Text] [Related]
18. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease. Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666 [TBL] [Abstract][Full Text] [Related]
19. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111 [TBL] [Abstract][Full Text] [Related]
20. Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Gokhale M; Girman C; Chen Y; Pate V; Funk MJ; Stürmer T Pharmacoepidemiol Drug Saf; 2016 May; 25(5):512-20. PubMed ID: 26860956 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]